Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M57.6Revenue $M0.0Net Margin (%)-265,381.8Altman Z-Score-11.3
Enterprise Value $M36.2EPS $-1.2Operating Margin %-265,381.8Piotroski F-Score3
P/E(ttm)--Beneish M-Score-3.8Pre-tax Margin (%)-265,381.8Higher ROA y-yN
Price/Book3.110-y EBITDA Growth Rate %-16.3Quick Ratio7.4Cash flow > EarningsY
Price/Sales--5-y EBITDA Growth Rate %14.1Current Ratio7.4Lower Leverage y-yY
Price/Free Cash Flow--y-y EBITDA Growth Rate %--ROA % (ttm)-87.9Higher Current Ratio y-yN
Dividend Yield %--PEG--ROE % (ttm)-95.5Less Shares Outstanding y-yN
Payout Ratio %--Shares Outstanding M24.3ROIC % (ttm)--Gross Margin Increase y-yN

Gurus Latest Trades with RPRX

Number of guru portfolios checked: 68.
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
RPRXJohn Paulson 2014-12-31 Sold Out -0.04%$6.02 - $10.69
($8.49)
$ 2.37-72%Sold Out0
RPRXJohn Paulson 2014-09-30 Buy 0.04%$8.77 - $22.16
($14.84)
$ 2.37-84%New holding1,000,000
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

RPRX is held by these investors:

No Entry found in the selected group of Gurus. You can
Premium Most recent portfolio changes are included for Premium Members only!


RPRX: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
PODOLSKI JOSEPHPresident and CEO 2016-02-18Buy10,000$0.93154.84view
PODOLSKI JOSEPHPresident and CEO 2016-01-07Buy11,677$1.18100.85view
Anderson KatherineCFO 2014-11-12Buy3,500$9.41-74.81view
PODOLSKI JOSEPHPresident and CEO 2014-11-12Buy4,700$9.42-74.84view
Masterson Nola EDirector 2014-09-15Buy200$14.34-83.47view
PODOLSKI JOSEPHPresident and CEO 2014-08-14Buy2,100$13.91-82.96view
Anderson KatherineCFO 2014-08-14Buy2,000$13.85-82.89view
CAIN DANIEL FDirector 2013-11-12Buy500$14.97-84.17view
PODOLSKI JOSEPHPresident and CEO 2013-10-25Buy3,000$18.03-86.86view
Anderson KatherineCFO 2013-10-25Buy1,000$17.9-86.76view

Quarterly/Annual Reports about RPRX:

News about RPRX:

Articles On GuruFocus.com
Weekly CFO Buys Highlight: RPRX, ARCT, LUB, JCS, DCIN Apr 23 2012 
Repros Therapeutics Inc. Reports Operating Results (10-Q) Nov 10 2010 
Repros Therapeutics Inc. Reports Operating Results (10-Q) Aug 09 2010 
Repros Therapeutics Inc. Reports Operating Results (10-Q) May 10 2010 
Repros Therapeutics Inc. Reports Operating Results (10-Q) Nov 09 2009 
Repros Therapeutics Inc. Reports Operating Results (10-Q) Aug 17 2009 
Repros Therapeutics Inc. Reports Operating Results (10-Q) May 11 2009 
Repros Therapeutics Inc. (RPRX) CEO Joseph Podolski buys 4,000 Shares Mar 05 2009 
Weekly CEO Buys Highlight: Medtox Scientific Inc., Provident Bankshares Corp., Escalade Inc., Repros Apr 25 2008 

More From Other Websites
Be Wary of These Five Tanking Stocks Today, Office Depot Among Them Apr 20 2016
These Four Biotech Stocks Are Trading With Massive Volume Today Apr 19 2016
Why Disney (DIS), Amedica (AMDA), Cvent (CVT), UniPixel (UNXL), and Repros Therapeutics (RPRX) Are... Apr 18 2016
Trending Stocks: Investors Have Found Interest In These Four Nasdaq Stocks on Monday Apr 18 2016
Repros to drop testosterone drug in U.S. if key study fails Apr 14 2016
Trending Stocks: Thursday's Top Trading Stock Investors Have Followed Apr 14 2016
What’s the Deal With These 5 Stocks on the Move Today? Apr 14 2016
Repros Therapeutics given time to rally Apr 14 2016
4 Small Cap Stocks That Have To Be On Your Watchlist Today Apr 14 2016
Repros Therapeutics (RPRX) Announces Significant Data for Proellex Phase 2 Meeting with the FDA to... Apr 13 2016
Repros Reveals Positive Data on Proellex for Uterine Fibroids Apr 13 2016
These Small Cap Stocks Are Getting Big Time Attention Today Apr 13 2016
REPROS THERAPEUTICS INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and... Apr 12 2016
Repros Reports Positive Clinical Data for Vaginal Proellex® in Women With Severe Menstrual Bleeding... Apr 12 2016
REPROS THERAPEUTICS INC. Financials Mar 17 2016
Repros Gives EU Update on Secondary Hypogonadism Drug Mar 16 2016
REPROS THERAPEUTICS INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and... Mar 15 2016
Repros Announces Initiation of Formal Approval Process by the European Medicines Agency Mar 15 2016
Repros Incurs Narrower-than-Expected Loss in Q4, Shares Up Mar 15 2016
Repros Therapeutics reports 4Q loss Mar 14 2016

Add Notes, Comments

If you want to ask a question or report a bug, please create a support ticket.
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)